Sotalol hydrochloride (Betapace), recently released by the Food and Drug Administration for general use, is used to treat a variety of ventricular and supraventricular tachyarrhythmias. The drug's dominant action is the result of combined nonselective beta-adrenergic antagonism (Class II effect) and monophasic action potential duration prolongation in all cardiac tissues (Class III effect). It causes less left ventricular depression than propranolol and has a low incidence of toxicity. It is a useful addition to the antiarrhythmic drug armamentarium. This article reviews the drug's pharmacokinetic, pharmacodynamic and electrophysiologic properties, clinical uses and potential side effects. Reports on the drug's use as an antianginal and antihypertensive agent are also discussed.
Skip Nav Destination
Articles| September 01 1993
Sotalol hydrochloride (Betapace): a new antiarrhythmic drug
Search for other works by this author on:
Am J Crit Care (1993) 2 (5): 397–406.
CS Dunnington; Sotalol hydrochloride (Betapace): a new antiarrhythmic drug. Am J Crit Care 1 September 1993; 2 (5): 397–406. doi: https://doi.org/10.4037/ajcc19188.8.131.527
Download citation file:
Don't already have an account? Register
AACN AccountSign In
Sign in via your InstitutionSign in via your Institution
Subscribe online and gain access to the entire archive.
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access